| International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study F Pagès, B Mlecnik, F Marliot, G Bindea, FS Ou, C Bifulco, A Lugli, ... The Lancet 391 (10135), 2128-2139, 2018 | 2003 | 2018 |
| Towards the introduction of the ‘Immunoscore’in the classification of malignant tumours J Galon, B Mlecnik, G Bindea, HK Angell, A Berger, C Lagorce, A Lugli, ... The Journal of pathology 232 (2), 199-209, 2014 | 1580 | 2014 |
| Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016 A Lugli, R Kirsch, Y Ajioka, F Bosman, G Cathomas, H Dawson, ... Modern pathology 30 (9), 1299-1311, 2017 | 1064 | 2017 |
| Cancer classification using the Immunoscore: a worldwide task force J Galon, F Pagès, FM Marincola, HK Angell, M Thurin, A Lugli, I Zlobec, ... Journal of translational medicine 10, 1-10, 2012 | 1001 | 2012 |
| Coordinated cellular neighborhoods orchestrate antitumoral immunity at the colorectal cancer invasive front CM Schürch, SS Bhate, GL Barlow, DJ Phillips, L Noti, I Zlobec, P Chu, ... Cell 182 (5), 1341-1359. e19, 2020 | 756 | 2020 |
| Clinical impact of programmed cell death ligand 1 expression in colorectal cancer RA Droeser, C Hirt, CT Viehl, DM Frey, C Nebiker, X Huber, I Zlobec, ... European journal of cancer 49 (9), 2233-2242, 2013 | 524 | 2013 |
| Synaptic proximity enables NMDAR signalling to promote brain metastasis Q Zeng, IP Michael, P Zhang, S Saghafinia, G Knott, W Jiao, BD McCabe, ... Nature 573 (7775), 526-531, 2019 | 437 | 2019 |
| High frequency of tumor‐infiltrating FOXP3+ regulatory T cells predicts improved survival in mismatch repair‐proficient colorectal cancer patients DM Frey, RA Droeser, CT Viehl, I Zlobec, A Lugli, U Zingg, D Oertli, ... International journal of cancer 126 (11), 2635-2643, 2010 | 418 | 2010 |
| Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget I Zlobec, A Lugli Oncotarget 1 (7), 651, 2010 | 378 | 2010 |
| Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer A Lugli, G Iezzi, I Hostettler, MG Muraro, V Mele, L Tornillo, V Carafa, ... British journal of cancer 103 (3), 382-390, 2010 | 377 | 2010 |
| Prognostic and predictive factors in colorectal cancer I Zlobec, A Lugli Postgraduate medical journal 84 (994), 403-411, 2008 | 333 | 2008 |
| Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a ‘fusion’pathway to colorectal cancer JR Jass, K Baker, I Zlobec, T Higuchi, M Barker, D Buchanan, J Young Histopathology 49 (2), 121-131, 2006 | 324 | 2006 |
| Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study E Domingo, L Freeman-Mills, E Rayner, M Glaire, S Briggs, L Vermeulen, ... The lancet Gastroenterology & hepatology 1 (3), 207-216, 2016 | 323 | 2016 |
| Clinicopathological and protein characterization of BRAF‐and K‐RAS‐mutated colorectal cancer and implications for prognosis I Zlobec, MP Bihl, H Schwarb, L Terracciano, A Lugli International journal of cancer 127 (2), 367-380, 2010 | 309 | 2010 |
| Tumor budding in colorectal cancer—ready for diagnostic practice? VH Koelzer, I Zlobec, A Lugli Human pathology 47 (1), 4-19, 2016 | 302 | 2016 |
| Tumour budding in solid cancers A Lugli, I Zlobec, MD Berger, R Kirsch, ID Nagtegaal Nature Reviews Clinical Oncology 18 (2), 101-115, 2021 | 282 | 2021 |
| Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles P Minoo, I Zlobec, M Peterson, L Terracciano, A Lugli International journal of oncology 37 (3), 707-718, 2010 | 275 | 2010 |
| Tumour budding: a promising parameter in colorectal cancer A Lugli, E Karamitopoulou, I Zlobec British journal of cancer 106 (11), 1713-1717, 2012 | 252 | 2012 |
| Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality? CA Fischer, I Zlobec, E Green, S Probst, C Storck, A Lugli, L Tornillo, ... International journal of cancer 126 (5), 1256-1262, 2010 | 244 | 2010 |
| Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer I Zlobec, R Steele, L Terracciano, JR Jass, A Lugli Journal of clinical pathology 60 (10), 1112-1116, 2007 | 239 | 2007 |
